Avenue Therapeutics (ATXI)

Largest owners	Shares	Value	Change
FBIO Fortress Biotech	1.05 mm	$787.00 k	-81.1%
CVI Investments	251.01 k	$0.00	0.0%
Intracoastal Capital	216.79 k	$616.00 k	0.0%
Geode Capital Management	52.57 k	$37.00 mm	0.0%
BK The Bank of New York Mellon Corporation	51.57 k	$36.46 mm	-2.7%
Vanguard	46.29 k	$32.73 mm	NEW
STT State Street	30.59 k	$21.53 mm	0.0%
Two Sigma Securities	14.44 k	$10.21 mm	NEW
Shikiar Asset Management	12.50 k	$9.00 k	NEW
Tower Research Capital	6.88 k	$4.86 mm	+22.2%

Largest transactions	Shares	Bought/sold	Change
FBIO Fortress Biotech	1.05 mm	-4.51 mm	-81.1%
Sabby Management	0.00	-553.34 k	EXIT
Vanguard	46.29 k	+46.29 k	NEW
Two Sigma Securities	14.44 k	+14.44 k	NEW
Shikiar Asset Management	12.50 k	+12.50 k	NEW
WFC Wells Fargo & Company	4.59 k	+4.59 k	NEW
BK The Bank of New York Mellon Corporation	51.57 k	-1.41 k	-2.7%
Tower Research Capital	6.88 k	+1.25 k	+22.2%
Advisor	500.00	+500.00	NEW
MS Morgan Stanley	276.00	-138.00	-33.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ATXI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Dec 24	Neil Herskowitz	COMMON STOCK, PAR VALUE $0.0001	Sell	Dispose S	No	No	2	23	46.00	97
5 Nov 24	Kranzler Jay D	COMMON STOCK, PAR VALUE $0.0001	Sell	Dispose S	No	No	2.24	61	136.64	559
30 Sep 24	Kranzler Jay D	COMMON STOCK, PAR VALUE $0.0001	Buy	Acquire P	No	No	2.5	497	1.24 k	620
27 Sep 24	Kranzler Jay D	COMMON STOCK, PAR VALUE $0.0001	Buy	Acquire P	No	No	2.4	3	7.20	123
23 Sep 24	Alexandra MacLean	COMMON STOCK, PAR VALUE $0.0001	Grant	Acquire A	No	No	0	170,000	0.00	170,000
23 Sep 24	Rosenwald Lindsay A MD	Employee stock option Common Stock	Grant	Acquire A	No	No	2.46	30,000	73.80 k	30,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Monday's Pre-Market Session

2 Dec 24

Avenue Therapeutics Q3 EPS $(1.92) Misses $(0.94) Estimate

14 Nov 24

Avenue Therapeutics (NASDAQ:ATXI) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of $(0.94) by 104.26 percent. This is a 139.51 percent decrease over earnings of $4.86 per

Press releases

From Benzinga Pro

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

14 Nov 24

MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the

Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit

9 Oct 24

MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for the